Foley Hoag Represents RedShift BioAnalytics in $20M Series E Financing

November 8, 2021

Foley Hoag LLP represented RedShift BioAnalytics Inc. (RedShiftBio), a company providing next-generation platform technology enabling measurement of previously undetectable structure changes in biomolecules, in the closing of its Series E Preferred Stock financing. The $20 million financing was led by Illumina Ventures and joined by all of the company’s current major investors, including Technology Venture Partners and Waters Corporation. Proceeds of the financing will be used to fund additional commercial expansion, continued technology innovation, and execution of its product development objectives. 

RedShiftBio, based in Burlington, MA, provides a novel life sciences platform for reliable and accurate detection of pivotal changes in molecular structure that affect the critical quality attributes governing the safety, efficacy, and stability of biomolecules and their raw materials. The company has developed a powerful new analytical technique, Microfluidic Modulation Spectroscopy (MMS), which provides in-depth structural information in a single automated analysis.

Foley Hoag attorneys Jeffrey Quillen, Kevin Lin and Mehack Ali represented RedShiftBio in the transaction. 

About Foley Hoag LLP

Foley Hoag is an award-winning, mid-sized, international law firm that focuses on innovative industries and high-stakes litigation. The diverse backgrounds, perspectives and experiences of our lawyers and business services professionals contribute to the exceptional service we deliver to clients. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.